Kannen V, Rasmussen M, Das S, Giuliana P, Izzati F, Choksi H
Front Immunol. 2025; 15:1513595.
PMID: 39867896
PMC: 11759301.
DOI: 10.3389/fimmu.2024.1513595.
Pan L, Huang H, Zhang P, Li H, Lu L, Wei M
J Cancer. 2024; 15(19):6239-6255.
PMID: 39513103
PMC: 11540515.
DOI: 10.7150/jca.101330.
Shao R, Visser I, Fros J, Yin X
Int J Biol Sci. 2024; 20(12):4585-4600.
PMID: 39309436
PMC: 11414379.
DOI: 10.7150/ijbs.98029.
de Andrade K, Cesar Cirne-Santos C
Pathogens. 2023; 12(12).
PMID: 38133344
PMC: 10747524.
DOI: 10.3390/pathogens12121461.
Goodier J, Wan H, Soares A, Sanchez L, Selser J, Pereira G
PLoS Genet. 2023; 19(7):e1010795.
PMID: 37405998
PMC: 10351740.
DOI: 10.1371/journal.pgen.1010795.
Roles of ADP-Ribosylation during Infection Establishment by Parasites.
Dowling J, Doig C
Pathogens. 2023; 12(5).
PMID: 37242378
PMC: 10223955.
DOI: 10.3390/pathogens12050708.
Recurrent Loss of Macrodomain Activity in Host Immunity and Viral Proteins.
Delgado-Rodriguez S, Ryan A, Daugherty M
Pathogens. 2023; 12(5).
PMID: 37242344
PMC: 10221186.
DOI: 10.3390/pathogens12050674.
Association of ZC3HAV1 single nucleotide polymorphisms with the susceptibility of Vogt-Koyanagi-Harada Disease.
Wu Q, Zhong Z, Zhou C, Cao Q, Su G, Yang P
BMC Med Genomics. 2023; 16(1):113.
PMID: 37221558
PMC: 10204004.
DOI: 10.1186/s12920-023-01546-3.
Mono-ADP-ribosylation by PARP10 inhibits Chikungunya virus nsP2 proteolytic activity and viral replication.
Krieg S, Pott F, Potthoff L, Verheirstraeten M, Butepage M, Golzmann A
Cell Mol Life Sci. 2023; 80(3):72.
PMID: 36840772
PMC: 9959937.
DOI: 10.1007/s00018-023-04717-8.
ADP-Ribosylation in Antiviral Innate Immune Response.
Du Q, Miao Y, He W, Zheng H
Pathogens. 2023; 12(2).
PMID: 36839575
PMC: 9964302.
DOI: 10.3390/pathogens12020303.
Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
Zhang D, Lu W, Zhuo Z, Mei H, Wu X, Cui Y
Discov Oncol. 2022; 13(1):78.
PMID: 35988113
PMC: 9393119.
DOI: 10.1007/s12672-022-00506-0.
ZAP isoforms regulate unfolded protein response and epithelial- mesenchymal transition.
Ly P, Xu S, Wirawan M, Luo D, Roca X
Proc Natl Acad Sci U S A. 2022; 119(31):e2121453119.
PMID: 35881805
PMC: 9351355.
DOI: 10.1073/pnas.2121453119.
The zinc proteome of SARS-CoV-2.
Andreini C, Arnesano F, Rosato A
Metallomics. 2022; 14(7).
PMID: 35767875
PMC: 9314716.
DOI: 10.1093/mtomcs/mfac047.
Diverse functions associate with non-coding polymorphisms shared between humans and chimpanzees.
Velazquez-Arcelay K, Benton M, Capra J
BMC Ecol Evol. 2022; 22(1):68.
PMID: 35606693
PMC: 9125839.
DOI: 10.1186/s12862-022-02020-x.
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs. 2022; 31(6):607-631.
PMID: 35435784
PMC: 9296104.
DOI: 10.1080/13543784.2022.2067527.
Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics.
Richard I, Burgess J, OByrne K, Bolderson E
Front Cell Dev Biol. 2022; 9:801200.
PMID: 35096828
PMC: 8795897.
DOI: 10.3389/fcell.2021.801200.
Development and Validation of Ten-RNA Binding Protein Signature Predicts Overall Survival in Osteosarcoma.
Zhang J, Miao X, Wu T, Jia J, Cheng X
Front Mol Biosci. 2021; 8:751842.
PMID: 34926575
PMC: 8671810.
DOI: 10.3389/fmolb.2021.751842.
The short isoform of the host antiviral protein ZAP acts as an inhibitor of SARS-CoV-2 programmed ribosomal frameshifting.
Zimmer M, Kibe A, Rand U, Pekarek L, Ye L, Buck S
Nat Commun. 2021; 12(1):7193.
PMID: 34893599
PMC: 8664833.
DOI: 10.1038/s41467-021-27431-0.
Interplay between ADP-ribosyltransferases and essential cell signaling pathways controls cellular responses.
Boehi F, Manetsch P, Hottiger M
Cell Discov. 2021; 7(1):104.
PMID: 34725336
PMC: 8560908.
DOI: 10.1038/s41421-021-00323-9.
Host ADP-ribosylation and the SARS-CoV-2 macrodomain.
Hoch N
Biochem Soc Trans. 2021; 49(4):1711-1721.
PMID: 34351418
PMC: 8421052.
DOI: 10.1042/BST20201212.